NasdaqGM:NTLABiotechs
Clinical Hold Lift On MAGNITUDE-2 Resets Risk Reward For Intellia Investors
Regulators have lifted the clinical hold on Intellia Therapeutics' MAGNITUDE-2 study, allowing the gene editing trial to resume.
The decision follows updates to safety protocols after rare adverse events were evaluated.
The cleared pathway enables expanded enrollment for MAGNITUDE-2 and continued work on Intellia's in vivo gene editing program.
For you as an investor looking at Intellia Therapeutics (NasdaqGM:NTLA), this regulatory step comes as the stock trades at $12.22. The share price...